Pharmaceutical 3822 articles

Beasley Allen has one of the largest and most technologically advanced Mass Torts practices in the country. The Mass Torts division represents numerous people in claims against companies that manufacture and/or market defective pharmaceuticals and/or medical devices. The resources devoted to this division allow the firm to competently and conscientiously handle any group of cases, no matter how large, along with particular catastrophic injury cases.

Our firm was recently involved in one of the greatest victories in Mass Torts history, against drug manufacturer Merck regarding the drug Vioxx. After more than five years of hard-fought and difficult litigation, Merck agreed to pay $4.85 billion, the largest pharmaceutical settlement in U.S. history, to resolve certain Vioxx-related claims involving plaintiffs who suffered a heart attack, including sudden cardiac death, or a stroke.

Metal hip component recalled due to poor performance


Medical device manufacturer Smith & Nephew is recalling a metal hip replacement component due to poor performance. The recall involves the 46mm diameter and smaller femoral heads and corresponding acetabular cup components for the BIRMINGHAM HIP Resurfacing (BHR) System. The company advises surgeons to maintain their routine follow-up protocol for patients. Patients are not required to take any new action at this time. “As part of its normal post-marketing surveillance, Smith & Nephew has conduced an analysis of recent National Joint Registry of England and Wales data,” the company announced in a press release. “This indicated … the revision rates associated ... Read More

Judge adds new plaintiffs to Ethicon transvaginal mesh lawsuit

transvaginal mesh

U.S. District Judge Joseph Goodwin, who is overseeing thousands of transvaginal mesh lawsuits in West Virginia, revised his plan for a single consolidated trial against Johnson & Johnson subsidiary Ethicon Inc., adding new plaintiffs and pushing back the start date by a month. The consolidated trial was to involve the lawsuits of 26 women who claimed Ethicon’s TVT was defectively designed and caused injuries. However, when new information came to light that some of the women in the lawsuit had been implanted with several transvaginal mesh devices, Judge Goodwin made changes to the plaintiffs list. The new consolidated lawsuit against Ethicon ... Read More

Experimental type 2 diabetes treatment fails in clinical trials


An experimental type 2 diabetes treatment made by Vitae Pharmaceuticals and Boehringer Ingelheim failed to significantly reduce blood sugar levels in patients when used with the first-line medication metformin, and analysts are wary that the medication will provide better results in trials testing it as a monotherapy. The drug was being tested as a treatment for obese patients with type 2 diabetes. The medication, currently known as VTP-34072, would have been the first drug in a class known as 11β-hydroxysteroid dehydrogenase type 1 inhibitor. It was discovered using Vitae’s Contour platform. VTP-34072 works by targeting an enzyme that produces a ... Read More

Eating citrus fruits may increase risk of melanoma


People who eat citrus fruits are more likely to develop melanoma, according to a new study published in the Journal of Clinical Oncology. The findings are based on a observational study conducted by researchers with the Warren Alpert Medical School of Brown University, Rhode Island Hospital, and the Channing Division of Network Medicine at Brigham and Women’s Hospital in Boston. Researchers used data from about 63,000 women and 41,000 men between the mid-1980s and 2010, and found that those who consumed citrus between two to four times a week had a 10 percent increased risk of developing melanoma. The reason ... Read More

Anesthesia system recalled due to manufacturing defect


Maquet is recalling its FLOW-I Anesthesia Systems after receiving several complaints where patient cassettes, which are the center of gas flow in the system, have come loose, which can prevent the ventilator from providing breathing support. While no injuries or deaths have been reported, this issue could cause serious injury or death in patients. Maquet has received 10 reports of this malfunction. The issue is that the patient cassette locking device may accidentally release the patient cassette from its mount when users perform a change of system. This may cause anesthesia gas to leak and could prevent the ventilator from providing ... Read More

Leukemia drug can make cancer more aggressive


PI3K inhibitors, a class of drugs used to treat leukemia and two types of lymphoma, when used as a monotherapy may actually make a patient’s cancer more aggressive and metastatic, according to a new study published in the journal Proceedings of the National Academy of Sciences. The only FDA-approved PI3K inhibitor is the brand name Idelalisib, which entered the market in July 2014. Several other drugs in the class are currently in development and being tested as a treatment for other cancers, including colorectal cancer, multiple myeloma and chronic lymphocytic leukemia, and inflammatory respiratory disease. The enzyme PI3K, or phosphatidylinositol-3 ... Read More

FDA warns consumers about unapproved prescription ear drops

Ear - Earrr by צביה Licensed under CC BY-SA 3.0 via Wikimedia Commons

The Food and Drug Administration (FDA) is vowing to come down hard on drug companies who are manufacturing and selling unapproved prescription ear drops labeled to relieve ear pain, infection, and inflammation. The ear drops contain active ingredients such as benzocaine and hydrocortisone, which have not been evaluated by the FDA for safety, effectiveness and quality. The agency has informed the companies that manufacture these illegal ear drops to stop or face enforcement actions including seizure, injunction, and/or criminal proceedings. The agency said that the drops’ labels do not indicate that they are not FDA approved, thus health care professionals may ... Read More

FDA investigates safety of codeine in children’s cough and cold medicine

children-smiling for WEB

Children younger than 18 who have suffered serious side effects after taking cough and cold medicine containing codeine has prompted the Food and Drug Administration (FDA) to launch an investigation into the safety of the medications in children. Side effects include slowed or difficult breathing. Children with breathing problems may be more susceptible to respiratory adverse events. In April, the European Medicines Agency (EMA) banned the use of codeine to treat coughs and colds in children younger than age 12, and recommended the drug not be used in children and adolescents between 12 and 18 who have breathing problems, such as asthma. The ... Read More

SSRIs linked to bone fractures in menopausal, postmenopausal women

Blue pills

Menopausal women who take a class of commonly prescribed antidepressants are more likely to break a bone compared to women who did not take the drugs, according to a new study published in the British Medical Journal. Menopause can cause a host of symptoms from hot flashes and mood changes including depression. They are also prone to osteoporosis, a condition that causes bones to become weak and brittle to the point that a fall or even mild stresses like bending over or coughing can cause a fracture. To treat mood symptoms associated with menopause, some doctors have turned to a ... Read More

New weight loss treatment carries cancer risks

bathroom scale

A new weight loss treatment is available to obese patients but researchers warn the drug has been linked to serious side effects, including cancer risks. The new iinjectable obesity drug, Saxenda, was approved late last year by the Food and Drug Administration (FDA) for patients with a BMI of 30 or more, or for patients with a BMI of 27 with at least one other weight-related condition, such as high blood pressure. The active ingredient, liraglutide, is the same drug in the type 2 diabetes treatment Victoza. Saxenda, however, contains a higher dose than Victoza. New patients will be required ... Read More